|

HPB-092 tablet Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Hangzhou Polymed Biopharmaceuticals, Inc.1

Indications

  • Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)1
  • Cancer1

Other1 trial

HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.